Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Efficacy of Orbital Radiotherapy in Moderate-to-Severe Active Graves’ Orbitopathy Including Long-Lasting Disease: A Retrospective Analysis
source: Radiation Oncology
authors: Jin Hwa Choi, Jeong Kyu Leesummary/abstract:
We aimed to explore the efficacy of orbital radiotherapy (RT) in patients with moderate-to-severe active Graves’ orbitopathy (GO), including long-lasting disease, and to determine the predictive factors associated with treatment response.
This was a retrospective study of 62 moderate-to-severe active GO patients treated with RT. Demographic data and ophthalmic findings prior to RT and at 3 and 6 months afterward were analyzed. Computed tomography was performed before and after RT to compare orbital volume change. We used logistic regression to determine the predictive factors for treatment response. Subjects were divided into early- and late-active phase groups based on GO duration of 24 months and treatment outcomes were compared with each other to observe the effects of RT timing on treatment response.
Forty (64.5%) and forty-six (74.1%) patients experienced improvements in GO at 3 and 6 months after radiotherapy, respectively. Ocular parameters such as clinical activity score (CAS), proptosis, extraocular muscle (EOM) limitation, and compressive optic neuropathy (CON) were improved by RT. Volumes of EOM significantly decreased after RT. The enlargement of EOMs and EOM limitation were predictive factors for a good response to RT. At 6 months after RT, 22 (68.8%) patients of late-active phase group exhibited improvement in GO, which is comparable to the number of 24 (80.0%) patients of early-active phase group. In the late-active phase group, CAS, diplopia, and visual acuity were improved significantly, but there was no change in EOM limitation.
In moderate-to-severe active GO patients, orbital RT may help improve high CAS, proptosis, EOM limitation, and CON. The orbital RT in long-lasting active GO patients may be considered as treatments for the relief of symptoms including high CAS and poor visual acuity.
Shannath Louise Merbs, MD, PhD, FACSShannath Louise Merbs is a fellowship-tr...
Graves’ and Thyroid Eye Disease Support Group MeetingThis event is hosted by Graves' Dise...
Quality of Life Remains Poor in People With Thyroid Eye Diseasehttps://www.youtube.com/watch?v=fwYlJ_pt...
Catherine J. Hwang, MDDr. Catherine J. Hwang was born in New Y...
Contour Variability in Thyroid Eye Disease With Compressive Optic Neuropathy Treated With Radiation TherapyPurpose: Few studies have evaluated t...
Casey Eye Institute – Thyroid Eye Disease CenterAs part of Oregon Health & Science U...
The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves’ Ophthalmopathy PatientsPurpose: The purpose of this study is t...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.